Regeneron Pharma (REGN) Selloff Is A Buying Opportunity - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $480.00 price target on Regeneron Pharma (NASDAQ: REGN) after the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
